DD295990A5 - Waessriges doxorubicin - Google Patents

Waessriges doxorubicin Download PDF

Info

Publication number: DD295990A5
Authority: DD; German Democratic Republic
Prior art keywords: solution; doxorubicin; range; physiologically acceptable; water
Prior art date: 1988-12-05

Application number

DD89335266A

Other languages

German (de)

English (en)

Inventor

Murray A Kaplan

Robert K Perrone

Joseph B Bogardus

Original Assignee

��`��@��@��k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-12-05

Filing date

1989-12-05

Publication date

1991-11-21

1989-12-05 Application filed by ��`��@��@��k�� filed Critical ��`��@��@��k��

1991-11-21 Publication of DD295990A5 publication Critical patent/DD295990A5/de

Links

AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 title claims abstract description 53
229960004679 doxorubicin Drugs 0.000 title claims abstract description 43
239000000243 solution Substances 0.000 claims abstract description 75
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
239000007864 aqueous solution Substances 0.000 claims abstract description 13
150000003839 salts Chemical class 0.000 claims abstract description 12
239000002253 acid Substances 0.000 claims abstract description 7
YNJORDSKPXMABC-UHFFFAOYSA-M sodium;2-hydroxypropane-2-sulfonate Chemical compound [Na+].CC(C)(O)S([O-])(=O)=O YNJORDSKPXMABC-UHFFFAOYSA-M 0.000 claims abstract 4
MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims description 26
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 20
238000000034 method Methods 0.000 claims description 10
239000000203 mixture Substances 0.000 claims description 9
229960002918 doxorubicin hydrochloride Drugs 0.000 claims description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
238000007911 parenteral administration Methods 0.000 claims description 6
230000000087 stabilizing effect Effects 0.000 claims description 6
239000011261 inert gas Substances 0.000 claims description 3
238000009472 formulation Methods 0.000 claims 7
239000008194 pharmaceutical composition Substances 0.000 claims 2
239000003963 antioxidant agent Substances 0.000 abstract description 14
230000003078 antioxidant effect Effects 0.000 abstract description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
235000006708 antioxidants Nutrition 0.000 description 13
229910052757 nitrogen Inorganic materials 0.000 description 13
YNJORDSKPXMABC-UHFFFAOYSA-N sodium;2-hydroxypropane-2-sulfonic acid Chemical compound [Na+].CC(C)(O)S(O)(=O)=O YNJORDSKPXMABC-UHFFFAOYSA-N 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 6
239000002552 dosage form Substances 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000011521 glass Substances 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 4
-1 hydroxymercapto Chemical class 0.000 description 4
238000010926 purge Methods 0.000 description 4
UOULCEYHQNCFFH-UHFFFAOYSA-M sodium;hydroxymethanesulfonate Chemical compound [Na+].OCS([O-])(=O)=O UOULCEYHQNCFFH-UHFFFAOYSA-M 0.000 description 4
239000004250 tert-Butylhydroquinone Substances 0.000 description 4
235000019281 tert-butylhydroquinone Nutrition 0.000 description 4
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000002585 base Substances 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
229960004106 citric acid Drugs 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 2
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
239000004809 Teflon Substances 0.000 description 2
229920006362 Teflon® Polymers 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
229940045942 acetone sodium bisulfite Drugs 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000003708 ampul Substances 0.000 description 2
229960004543 anhydrous citric acid Drugs 0.000 description 2
230000003466 anti-cipated effect Effects 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000005846 sugar alcohols Chemical class 0.000 description 2
RMZNXRYIFGTWPF-UHFFFAOYSA-N 2-nitrosoacetic acid Chemical compound OC(=O)CN=O RMZNXRYIFGTWPF-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000427202 Adria Species 0.000 description 1
IBZGBXXTIGCACK-CWKPULSASA-N Adriamycinone Chemical compound C1[C@@](O)(C(=O)CO)C[C@H](O)C2=C1C(O)=C1C(=O)C(C=CC=C3OC)=C3C(=O)C1=C2O IBZGBXXTIGCACK-CWKPULSASA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
101000823778 Homo sapiens Y-box-binding protein 2 Proteins 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
241000187081 Streptomyces peucetius Species 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000003972 antineoplastic antibiotic Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000007872 degassing Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000005308 flint glass Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229910001504 inorganic chloride Inorganic materials 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
229910052756 noble gas Inorganic materials 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
QNLDTXPVZPRSAM-DTOXXUQYSA-N pentazocine lactate Chemical compound CC(O)C(O)=O.C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 QNLDTXPVZPRSAM-DTOXXUQYSA-N 0.000 description 1
229960001246 pentazocine lactate Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
239000003186 pharmaceutical solution Substances 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920002492 poly(sulfone) Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
229960001309 procaine hydrochloride Drugs 0.000 description 1
239000000473 propyl gallate Substances 0.000 description 1
235000010388 propyl gallate Nutrition 0.000 description 1
229940075579 propyl gallate Drugs 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
229940035024 thioglycerol Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)
Lubricants (AREA)
Lubrication Of Internal Combustion Engines (AREA)

DD89335266A 1988-12-05 1989-12-05 Waessriges doxorubicin DD295990A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US27962788A	1988-12-05	1988-12-05

Publications (1)

Publication Number	Publication Date
DD295990A5 true DD295990A5 (de)	1991-11-21

Family

ID=23069771

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD89335266A DD295990A5 (de)	1988-12-05	1989-12-05	Waessriges doxorubicin

Country Status (20)

Country	Link
EP (1)	EP0372888B1 (fr)
JP (1)	JPH02200637A (fr)
KR (1)	KR920001460B1 (fr)
AT (1)	ATE78402T1 (fr)
AU (1)	AU612916B2 (fr)
DD (1)	DD295990A5 (fr)
DE (1)	DE68902223T2 (fr)
DK (1)	DK609889A (fr)
ES (1)	ES2044148T3 (fr)
FI (1)	FI895733A7 (fr)
GR (1)	GR3005391T3 (fr)
HU (1)	HU204704B (fr)
IE (1)	IE893867L (fr)
IL (1)	IL92541A0 (fr)
NO (1)	NO894811L (fr)
NZ (1)	NZ231602A (fr)
OA (1)	OA09898A (fr)
PT (1)	PT92483B (fr)
YU (1)	YU226189A (fr)
ZA (1)	ZA899248B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006085336A2 (fr) *	2005-02-11	2006-08-17	Dabur Pharma Limited	Compositions pharmaceutiques stabilisees comprenant un glycoside d'anthracycline
US11213538B2 (en)	2016-02-16	2022-01-04	General Incorporated Association Pharma Valley Project Supporting Organization	Agent for overcoming immunosuppression and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8519452D0 (en) *	1985-08-02	1985-09-11	Erba Farmitalia	Injectable solutions
FI883338A7 (fi) *	1987-07-16	1989-01-17	Bristol Myers Squibb Co	Doksorubisiinihydrokloridin vesiliuoksia

1989
- 1989-11-30 FI FI895733A patent/FI895733A7/fi not_active Application Discontinuation
- 1989-12-01 NZ NZ231602A patent/NZ231602A/en unknown
- 1989-12-01 NO NO89894811A patent/NO894811L/no unknown
- 1989-12-04 IL IL92541A patent/IL92541A0/xx unknown
- 1989-12-04 OA OA59689A patent/OA09898A/fr unknown
- 1989-12-04 AT AT89312625T patent/ATE78402T1/de not_active IP Right Cessation
- 1989-12-04 ZA ZA899248A patent/ZA899248B/xx unknown
- 1989-12-04 YU YU02261/89A patent/YU226189A/xx unknown
- 1989-12-04 DK DK609889A patent/DK609889A/da not_active Application Discontinuation
- 1989-12-04 JP JP1315123A patent/JPH02200637A/ja active Pending
- 1989-12-04 EP EP89312625A patent/EP0372888B1/fr not_active Expired - Lifetime
- 1989-12-04 DE DE8989312625T patent/DE68902223T2/de not_active Expired - Fee Related
- 1989-12-04 IE IE893867A patent/IE893867L/xx unknown
- 1989-12-04 KR KR1019890017864A patent/KR920001460B1/ko not_active Expired
- 1989-12-04 PT PT92483A patent/PT92483B/pt not_active IP Right Cessation
- 1989-12-04 ES ES89312625T patent/ES2044148T3/es not_active Expired - Lifetime
- 1989-12-05 AU AU45915/89A patent/AU612916B2/en not_active Ceased
- 1989-12-05 HU HU896426A patent/HU204704B/hu not_active IP Right Cessation
- 1989-12-05 DD DD89335266A patent/DD295990A5/de not_active IP Right Cessation
1992
- 1992-08-10 GR GR920400652T patent/GR3005391T3/el unknown

Also Published As

Publication number	Publication date
NZ231602A (en)	1991-12-23
NO894811D0 (no)	1989-12-01
PT92483B (pt)	1995-08-09
NO894811L (no)	1990-06-06
HU896426D0 (en)	1990-02-28
HU204704B (en)	1992-02-28
DK609889D0 (da)	1989-12-04
JPH02200637A (ja)	1990-08-08
FI895733A0 (fi)	1989-11-30
ES2044148T3 (es)	1994-01-01
DK609889A (da)	1990-06-06
YU226189A (en)	1991-02-28
AU612916B2 (en)	1991-07-18
IE893867L (en)	1990-06-05
KR920001460B1 (ko)	1992-02-14
ATE78402T1 (de)	1992-08-15
EP0372888B1 (fr)	1992-07-22
DE68902223T2 (de)	1993-01-14
HUT52961A (en)	1990-09-28
IL92541A0 (en)	1990-08-31
FI895733A7 (fi)	1990-06-06
KR900009081A (ko)	1990-07-02
AU4591589A (en)	1990-06-07
PT92483A (pt)	1990-06-29
GR3005391T3 (fr)	1993-05-24
DE68902223D1 (de)	1992-08-27
EP0372888A1 (fr)	1990-06-13
ZA899248B (en)	1990-08-29
OA09898A (fr)	1994-09-15

Legal Events

Date	Code	Title	Description
1995-10-26	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DE69913138T2 (de)	2004-08-26	Stabilisierte zusammensetzung mit nootropen wirkstoffen
DE69824277T2 (de)	2004-09-23	Stabile medizinische zusammenstellungen die 4,5-epoxymorphinanderivate enthalten
DE69005992T2 (de)	1994-05-05	Psychotropische Wirkstoffe enthaltende stabilisierte Lösungen.
DE602005001833T2 (de)	2008-04-17	Zusammensetzungen enthaltend Ecteinascidin und einen Disaccharide
CH694396A5 (de)	2004-12-31	Pharmazeutische Zusammensetzung mit therapeutischem oder pharmazeutischem Mittel und Edetat.
WO2008064854A1 (fr)	2008-06-05	Préparation pharmaceutique de tramadol et acétaminophène
DE69004066T2 (de)	1994-02-17	Verfahren zur photostabilisierung von augenspüllösungen.
DE3042332A1 (de)	1981-05-21	Waessrige nitroglycerinloesung
DE602005002653T2 (de)	2008-07-17	Stabilisierte zusammensetzungen mit einem therapeutischen wirkstoff; zitronensäure oder einer konjugierten base und chlordioxid
DE60117467T2 (de)	2006-09-28	Famotidin-injektionen
DE60305687T2 (de)	2007-02-22	Wässrige injizierbare Suspensionen für Tiere enthaltend Florfenicol
DE69819770T2 (de)	2004-09-23	Anästhetikum
DE69808793T2 (de)	2003-07-24	Pharmazeutische zusammensetzungen aus dalfopristine und quinupristine und verfahren zu ihrer herstellung
CH676549A5 (fr)	1991-02-15
DE3751589T2 (de)	1996-05-02	Anthracyclin-Glucosid enthaltende einspritzbare gebrauchsfertige Lösungen gegen Krebs.
DE3876160T2 (de)	1993-04-01	Nichtwaessrige loesung von doxorubicinhydrochlorid.
DE69016087T2 (de)	1995-05-24	Stabile Lösungen von Rebeccamycinderivaten sowie deren Herstellung.
DD295990A5 (de)	1991-11-21	Waessriges doxorubicin
DE69130844T2 (de)	1999-06-10	Suspendierfähige Sirupe
DE60001489T2 (de)	2003-12-04	Pharmazeutische zubereitung für die intravenöse oder intramuskuläre verabreichung von octreotid
DE69232409T2 (de)	2002-11-07	Ungepufferte, vorgemischte ranitidin-formulierung
AT401469B (de)	1996-09-25	Pharmazeutische wässrige lösung zur parenteralen anwendung enthaltend einen in situ gebildeten komplex von einem alkaloid mit bis-indol-gerüst, sowie verfahren zu deren herstellung
EP2142169B1 (fr)	2011-10-26	Préparation pharmaceutique aqueuse
DE4396086B3 (de)	2013-02-28	Sirup mit N-Acetylcystein
WO2002026233B1 (fr)	2002-07-04	Solution pour perfusion de ciprofloxacine stable au stockage et a teneur reduite en acide